Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Shah, Sunish; Bremmer, Derek N.; Kline, Ellen G.; Nicolau, David P.; Shields, Ryan K.
• Is Part Of: Journal of infection and chemotherapy. Volume 28:Issue 1(2022)
• Page Start: 87
• Page End: 90
• Publication Date: 2022-01
• Subjects: Ceftolozane -- Tazobactam -- Endocarditis -- Pseudomonas -- Drug-resistant; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2021.08.013
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: We describe a case of a 48 years old male with left sided endocarditis and septic emboli secondary to a Pseudomonas aeruginosa strain that developed resistance to other β-lactam antibiotics during therapy resulting in prolonged bacteremia. Blood cultures sterilized within 1 day of initiating ceftolozane/tazobactam 3 g every 8 hours in combination with ciprofloxacin. Steady state free ceftolozane plasma Cmax and Cmin concentrations were calculated to be 122.2μg/mL and 24.3μg/mL, respectively. The multidrug-resistant strain harbored chromosomal β-lactamases OXA-486 and PDC-3, mutations in ampD and dacB predicted to lead to ampC over-expression, and mutations in OprD predicted to decrease outer membrane permeability. Following completion of a 42 day course and aortic valve replacement, the patient was deemed clinically cured without recurrence of infection at follow up 2 years later. To our knowledge, this is the first reported case to measure ceftolozane concentrations during the treatment of endocarditis which supports dose optimization approaches of severe endovascular disease due to multidrug resistant pathogens.